Lineweaver Wealth Advisors LLC Buys 433 Shares of Eli Lilly and Company $LLY

Key Points

• Lineweaver Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 18.7% during the 2nd quarter, adding 433 shares to reach a total of 2,752 shares valued at approximately $2.15 million.
• Eli Lilly reported a robust quarterly earnings of $6.31 per share, exceeding the consensus estimate by $0.72, along with a revenue increase of 37.6% year-over-year.
• The company recently announced a quarterly dividend of $1.50 per share, representing an annualized dividend of $6.00 with a yield of 0.8%.

Lineweaver Wealth Advisors LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 18.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,752 shares of the company's stock after purchasing an additional 433 shares during the period. Lineweaver Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $2,146,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the business. WestEnd Advisors LLC lifted its position in shares of Eli Lilly and Company by 210.0% in the 1st quarter. WestEnd Advisors LLC now owns 31 shares of the company's stock valued at $26,000 after acquiring an additional 21 shares in the last quarter. Wealth Preservation Advisors LLC purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $27,000. Citizens National Bank Trust Department lifted its position in shares of Eli Lilly and Company by 180.0% in the 1st quarter. Citizens National Bank Trust Department now owns 42 shares of the company's stock valued at $35,000 after acquiring an additional 27 shares in the last quarter. Financial Gravity Asset Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 1st quarter valued at approximately $40,000. Finally, Mascagni Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $43,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Eli Lilly and Company Price Performance

LLY traded down $9.41 during midday trading on Friday, hitting $753.52. The company had a trading volume of 7,319,147 shares, compared to its average volume of 3,181,974. The company has a debt-to-equity ratio of 1.86, a quick ratio of 1.00 and a current ratio of 1.28. The company has a market capitalization of $713.18 billion, a PE ratio of 49.25, a P/E/G ratio of 1.06 and a beta of 0.47. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $939.86. The firm's 50-day simple moving average is $738.37 and its 200-day simple moving average is $771.89.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the previous year, the company earned $3.92 EPS. Eli Lilly and Company's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Equities research analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 10th. Investors of record on Friday, August 15th were paid a dividend of $1.50 per share. The ex-dividend date of this dividend was Friday, August 15th. This represents a $6.00 annualized dividend and a yield of 0.8%. Eli Lilly and Company's dividend payout ratio (DPR) is presently 39.22%.

Insider Transactions at Eli Lilly and Company

In related news, Director J Erik Fyrwald purchased 1,565 shares of the business's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average price of $642.33 per share, with a total value of $1,005,246.45. Following the completion of the purchase, the director owned 74,578 shares in the company, valued at $47,903,686.74. This represents a 2.14% increase in their position. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the stock in a transaction dated Tuesday, August 12th. The stock was acquired at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer directly owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last 90 days, insiders have purchased 4,514 shares of company stock valued at $2,894,841. 0.13% of the stock is currently owned by insiders.

Analyst Ratings Changes

Several equities research analysts recently commented on LLY shares. Hsbc Global Res upgraded shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research report on Wednesday, August 27th. Wall Street Zen lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday. Leerink Partners reiterated a "market perform" rating and issued a $715.00 price objective on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Daiwa America lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Finally, Leerink Partnrs lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have assigned a Hold rating to the company. According to data from MarketBeat.com, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and a consensus price target of $939.61.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.